1. Home
  2. NREF vs SABS Comparison

NREF vs SABS Comparison

Compare NREF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexPoint Real Estate Finance Inc.

NREF

NexPoint Real Estate Finance Inc.

N/A

Current Price

$12.17

Market Cap

298.0M

Sector

Real Estate

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.01

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NREF
SABS
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.0M
293.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NREF
SABS
Price
$12.17
$3.01
Analyst Decision
Hold
Strong Buy
Analyst Count
3
11
Target Price
★ $14.50
$11.64
AVG Volume (30 Days)
60.2K
★ 672.8K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 15.79%
N/A
EPS Growth
N/A
★ 78.53
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$4.78
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.60
$2.44
52 Week High
$18.43
$5.15

Technical Indicators

Market Signals
Indicator
NREF
SABS
Relative Strength Index (RSI) 24.86 48.54
Support Level N/A $2.44
Resistance Level $16.04 $4.03
Average True Range (ATR) 0.63 0.23
MACD -0.22 0.01
Stochastic Oscillator 2.51 38.33

Price Performance

Historical Comparison
NREF
SABS

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: